Institute of Neuroinformatics, D-ITET, ETH Zurich and UZH, Zurich, Switzerland.
Neuroscience Center, Zurich, Switzerland.
Nat Commun. 2020 Oct 1;11(1):4929. doi: 10.1038/s41467-020-18059-7.
Non-invasive, molecularly-specific, focal modulation of brain circuits with low off-target effects can lead to breakthroughs in treatments of brain disorders. We systemically inject engineered ultrasound-controllable drug carriers and subsequently apply a novel two-component Aggregation and Uncaging Focused Ultrasound Sequence (AU-FUS) at the desired targets inside the brain. The first sequence aggregates drug carriers with millimeter-precision by orders of magnitude. The second sequence uncages the carrier's cargo locally to achieve high target specificity without compromising the blood-brain barrier (BBB). Upon release from the carriers, drugs locally cross the intact BBB. We show circuit-specific manipulation of sensory signaling in motor cortex in rats by locally concentrating and releasing a GABA receptor agonist from ultrasound-controlled carriers. Our approach uses orders of magnitude (1300x) less drug than is otherwise required by systemic injection and requires very low ultrasound pressures (20-fold below FDA safety limits for diagnostic imaging). We show that the BBB remains intact using passive cavitation detection (PCD), MRI-contrast agents and, importantly, also by sensitive fluorescent dye extravasation and immunohistochemistry.
非侵入性、分子特异性、对大脑回路的低脱靶效应的局灶性调节,可以为脑疾病的治疗带来突破。我们系统性地注射工程化的超声可控药物载体,并随后在大脑内的目标部位施加一种新的双组分聚集和光解聚焦超声序列 (AU-FUS)。第一个序列通过数量级精确地聚集药物载体。第二个序列局部地使载体的货物解笼,从而实现高靶特异性,而不损害血脑屏障 (BBB)。从载体中释放后,药物局部穿过完整的 BBB。我们通过从超声控制的载体中局部浓缩和释放 GABA 受体激动剂,在大鼠的运动皮层中展示了对感觉信号的特定回路操纵。我们的方法使用的药物数量级(1300 倍)比全身注射所需的药物少得多,并且需要非常低的超声压力(低于 FDA 诊断成像安全限制的 20 倍)。我们使用被动空化检测 (PCD)、MRI 造影剂,重要的是,还使用敏感的荧光染料外渗和免疫组织化学,表明 BBB 保持完整。